Ken Griffin Biomarin Pharmaceutical Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 186,100 shares of BMRN stock, worth $13.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

186,100

Previous 60,900 205.58%

Holding current value

$13.1 Million

Previous $5.32 Million 188.04%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $106 Million - $131 Million	-1,417,706 Reduced 71.76%	557,852 $45.9 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $136 Million - $160 Million	1,620,613 Added 456.58%	1,975,558 $173 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $16.3 Million - $21 Million	213,413 Added 150.79%	354,945 $34.2 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $29 Million - $32.2 Million	-340,807 Reduced 70.66%	141,532 $12.5 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $31.1 Million - $36 Million	358,771 Added 290.34%	482,339 $41.8 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $608,301 - $813,032	-6,933 Reduced 5.31%	123,568 $12 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $70.6 Million - $94.7 Million	-871,813 Reduced 86.98%	130,501 $13.5 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $12.4 Million - $14.6 Million	-150,761 Reduced 13.07%	1,002,314 $85 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $67 Million - $81.4 Million	-937,328 Reduced 44.84%	1,153,075 $95.6 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $54.4 Million - $67.9 Million	732,488 Added 53.94%	2,090,403 $161 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $93.9 Million - $120 Million	1,308,848 Added 2667.47%	1,357,915 $120 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $68.1 Million - $77.9 Million	-911,095 Reduced 94.89%	49,067 $3.79 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $50.9 Million - $57.1 Million	-673,518 Reduced 41.23%	960,162 $80.1 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $102 Million - $123 Million	-1,361,590 Reduced 45.46%	1,633,680 $123 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $37.6 Million - $46.7 Million	517,914 Added 20.91%	2,995,270 $263 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $160 Million - $291 Million	2,222,384 Added 871.62%	2,477,356 $188 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $346,440 - $540,978	-4,355 Reduced 1.68%	254,972 $31.4 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $127 Million - $172 Million	-1,780,826 Reduced 87.29%	259,327 $21.9 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $18.2 Million - $24.4 Million	282,923 Added 16.1%	2,040,153 $172 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $39.6 Million - $50 Million	587,616 Added 50.24%	1,757,230 $118 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $3.29 Million - $3.85 Million	40,966 Added 3.63%	1,169,614 $100 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $19.3 Million - $22.6 Million	-229,037 Reduced 16.87%	1,128,648 $0
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $88.2 Million - $117 Million	-1,101,023 Reduced 44.78%	1,357,685 $116 Million
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $58.7 Million - $66.1 Million	625,303 Added 34.11%	2,458,708 $0
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $34.8 Million - $45.3 Million	457,896 Added 33.29%	1,833,405 $0
Q1 2018 May 11, 2018	SELL	$77.67 - $92.63 $73 Million - $87 Million	-939,566 Reduced 40.58%	1,375,509 $112 Million
Q4 2017 Feb 09, 2018	BUY	$80.76 - $95.13 $54.2 Million - $63.9 Million	671,639 Added 40.87%	2,315,075 $206 Million
Q3 2017 Nov 09, 2017	BUY	$80.6 - $94.95 $132 Million - $156 Million	1,643,436	1,643,436 $153 Million

Others Institutions Holding BMRN

# of Institutions

629

Shares Held

184M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account